Natalie Kreitzer, MD, MS
Associate Professor of Emergency Medicine
Department of Emergency Medicine
University of Cincinnati College of Medicine
Director of Stroke Services
West Chester Hospital
Cincinnati, USA
David Seiffge, MD
Professor of Neurology
Department of Neurology
Inselspital University Hospital Bern
University of Bern
Bern, Switzerland
Adrian R. Parry-Jones, MD, FRCP, PhD
Geoffrey Jefferson Brain Research Centre
University of Manchester
Manchester, UK
W. Brian Gibler, MD, FACEP, FACC, FAHA
EMCREG-International
University of Cincinnati College of Medicine
Cincinnati, USA
Full Accreditation and Program Information
13:15
–
Welcome & Introductions
13:20
–
Repletion or Reversal? Optimizing Specific Therapy for Direct Oral Anticoagulant (DOAC)-Related Life-Threatening Bleeding Using Real-World Experience - Dr. Natalie Kreitzer
13:35
–
Panel Discussion: Repletion Management for Vitamin K Antagonist Anticoagulation
13:43
–
Reversal of Factor Xa Inhibitor ICH: ANNEXA-4, ANNEXA-I and Real-World Evidence - Dr. David Seiffge
14:00
–
Panel Discussion: Specific Reversal Therapy for Factor Xa and Factor IIa Inhibitor-Associated ICH Life-Threatening Bleeding
14:10
–
Development of a Critical Care Pathway for Patients with ICH Using Specific Reversal Agents for Anticoagulated Patients with ICH - Dr. Adrian Parry-Jones
14:25
–
Panel Discussion: Reinforcement of Principles, Overcoming Treatment Barriers, and Improving Time to Treatment for ICH
Target Audience
This activity has been designed to meet the educational needs of the interprofessional team, including neurologists, neurointensivists, critical care specialists, emergency medicine, clinical cardiologists, hospital medicine, radiologists, neurosurgery, nurse practitioners, physician assistants, nurses, pharmacists as well as other clinicians involved in the management of patients with intracranial hemorrhages (ICH).
Learning Objectives
After completing this activity, the participant should be better able to:
- Employ appropriate treatment management strategies to address the critical clinical aspects of ICH and hematoma expansion
- Explain when and how to initiate appropriate reversal agents in ICH bleeds
- Discuss the need to develop and implement protocols and local care pathways based upon on existing evidence-based medicine guidelines to improve the management of ICH bleeds